Mineralys Therapeutics (NASDAQ:MLYS) Insider David Malcom Rodman Sells 416 Shares of Stock

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) insider David Malcom Rodman sold 416 shares of the firm’s stock in a transaction on Friday, April 17th. The shares were sold at an average price of $31.33, for a total value of $13,033.28. Following the transaction, the insider directly owned 69,792 shares of the company’s stock, valued at $2,186,583.36. This represents a 0.59% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

David Malcom Rodman also recently made the following trade(s):

• On Wednesday, April 15th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $27.66, for a total value of $175,585.68.
• On Monday, April 13th, David Malcom Rodman sold 14,058 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $26.54, for a total value of $373,099.32.
• On Thursday, April 9th, David Malcom Rodman sold 2,170 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $27.38, for a total value of $59,414.60.
• On Thursday, March 12th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $27.37, for a total value of $173,744.76.
• On Friday, March 13th, David Malcom Rodman sold 14,058 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $26.26, for a total value of $369,163.08.
• On Monday, March 9th, David Malcom Rodman sold 2,171 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $26.84, for a total value of $58,269.64.
• On Tuesday, February 17th, David Malcom Rodman sold 417 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $27.59, for a total value of $11,505.03.
• On Thursday, February 12th, David Malcom Rodman sold 6,349 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $28.99, for a total value of $184,057.51.
• On Friday, February 13th, David Malcom Rodman sold 14,055 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $27.44, for a total value of $385,669.20.
• On Monday, February 9th, David Malcom Rodman sold 2,171 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $30.21, for a total value of $65,585.91.

Mineralys Therapeutics Trading Down 4.3%

Shares of Mineralys Therapeutics stock opened at $28.78 on Wednesday. The firm has a market capitalization of $2.37 billion, a P/E ratio of -12.14 and a beta of 0.69. The business has a fifty day simple moving average of $27.24 and a two-hundred day simple moving average of $34.07. Mineralys Therapeutics, Inc. has a 12 month low of $12.59 and a 12 month high of $47.65.

Mineralys Therapeutics (NASDAQ:MLYS) last announced its quarterly earnings data on Thursday, March 12th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.17. Analysts predict that Mineralys Therapeutics, Inc. will post -2.28 earnings per share for the current year.

Analyst Upgrades and Downgrades

MLYS has been the subject of a number of analyst reports. Bank of America raised their price objective on shares of Mineralys Therapeutics from $46.00 to $51.00 and gave the company a “buy” rating in a research note on Friday, March 13th. Jefferies Financial Group restated a “hold” rating and set a $30.00 price objective on shares of Mineralys Therapeutics in a research note on Friday, March 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Mineralys Therapeutics in a research note on Thursday, January 22nd. HC Wainwright set a $56.00 price objective on shares of Mineralys Therapeutics and gave the company a “buy” rating in a research note on Tuesday, March 10th. Finally, Wall Street Zen upgraded shares of Mineralys Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, March 15th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Mineralys Therapeutics has an average rating of “Moderate Buy” and an average price target of $49.14.

Hedge Funds Weigh In On Mineralys Therapeutics

A number of hedge funds have recently bought and sold shares of MLYS. State Street Corp raised its position in Mineralys Therapeutics by 144.4% in the 4th quarter. State Street Corp now owns 3,184,999 shares of the company’s stock worth $115,584,000 after buying an additional 1,881,976 shares during the last quarter. Farallon Capital Management LLC purchased a new position in Mineralys Therapeutics in the 3rd quarter worth about $63,442,000. Price T Rowe Associates Inc. MD raised its position in Mineralys Therapeutics by 6,097.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,325,120 shares of the company’s stock worth $48,089,000 after buying an additional 1,303,737 shares during the last quarter. Holocene Advisors LP purchased a new position in Mineralys Therapeutics in the 3rd quarter worth about $45,708,000. Finally, Janus Henderson Group PLC lifted its position in Mineralys Therapeutics by 6,012.8% during the fourth quarter. Janus Henderson Group PLC now owns 1,213,265 shares of the company’s stock valued at $44,005,000 after purchasing an additional 1,193,417 shares during the period. Hedge funds and other institutional investors own 84.46% of the company’s stock.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.